Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study.

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)

These results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy.

Keyphrases

type diabetes
weight loss
bariatric surgery
cardiovascular disease
glycemic control
metabolic syndrome
stem cells
insulin resistance
adipose tissue
risk assessment
gastric bypass
mesenchymal stem cells
obese patients